Although PSMA-PET has no advantage in the differential diagnosis of metastases of PCa and other lesions, it may be used as alternative staging and to identify patients with liver primary malignant for PSMA-targeted therapy. This evidence concerns the gene FOLH1 and posterior cortical atrophy.